Country: Կանադա
language: անգլերեն
source: Health Canada
LOPERAMIDE HYDROCHLORIDE; SIMETHICONE
MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC
A07DA53
LOPERAMIDE, COMBINATIONS
2MG; 125MG
TABLET (CHEWABLE)
LOPERAMIDE HYDROCHLORIDE 2MG; SIMETHICONE 125MG
ORAL
5/10/20
OTC
ANTIDIARRHEA AGENTS
Active ingredient group (AIG) number: 0231812001; AHFS:
CANCELLED POST MARKET
2014-05-21
_ _ _ IMODIUM_ _®_ _ Complete _ _Page 1 of 22_ PRODUCT MONOGRAPH IMODIUM ® Complete Loperamide Hydrochloride, 2 mg/ Simethicone, 125 mg Oral antidiarrheal/antiflatulent agent McNeil Consumer Healthcare, Division of Johnson & Johnson Inc. 88 McNabb St. Markham, Ontario L3R 5L2 Date of Revision: May 22, 2019 Submission Control No: 225986 _ _ _ IMODIUM_ _®_ _ Complete _ _Page 2 of 22_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ........................................................................ 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 3 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................... 5 DRUG INTERACTIONS ................................................................................................... 8 DOSAGE AND ADMINISTRATION ............................................................................... 8 OVERDOSAGE .................................................................................................................. 9 ACTION AND CLINICAL PHARMACOLOGY ............................................................ 10 STORAGE AND STABILITY ......................................................................................... 11 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................. 11 PART II: SCIENTIFIC INFORMATION .............................................................................. 12 PHARMACEUTICAL INFORMATION ......................................................................... 12 CLINICAL TRIALS ........................................................................................... read_full_document